Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22425813 | 0.88 | KMT2A (0.58) | KMT2AMEN1FAAHMAPK1ALDH1A1 | |
| SCHEMBL2119932 | 0.86 | MEN1 (0.55) | KMT2AMEN1FAAHMAPK1ALDH1A1 | |
| SCHEMBL15887522 | 0.84 | MEN1 (0.53) | KMT2AMEN1FAAHMAPK1ALDH1A1 | |
| SCHEMBL26419977 | 0.83 | MAPK1 (0.47) | KMT2AMEN1FAAHMAPK1ALDH1A1 | |
| SCHEMBL2120346 | 0.82 | FAAH (0.61) | KMT2AMEN1FAAHMAPK1ALDH1A1 | |
| SCHEMBL19782337 | 0.82 | MEN1 (0.46) | KMT2AMEN1FAAHMAPK1ALDH1A1 | |
| SCHEMBL20078293 | 0.81 | ALDH1A1 (0.38) | KMT2AMEN1FAAHMAPK1ALDH1A1 | |
| SCHEMBL24212536 | 0.80 | MEN1 (0.44) | KMT2AMEN1FAAHMAPK1ALDH1A1 | |
| SCHEMBL26003951 | 0.80 | MEN1 (0.44) | KMT2AMEN1FAAHMAPK1ALDH1A1 | |
| SCHEMBL25083109 | 0.80 | MEN1 (0.44) | KMT2AMEN1FAAHMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871894-B2 | Production method of polyhydroxyimide | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-10-28 | — | — | US | disclosed |
| US-20120094232-A1 | PRODUCTION METHOD OF POLYHYDROXYIMIDE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | KMT2A 3828/4885MEN1 1549/4885FAAH 4134/4885 |
| US-20120094232-A1 | PRODUCTION METHOD OF POLYHYDROXYIMIDE | GRHPR, MRPL21, F12 | KMT2A 930/4885MEN1 2948/4885FAAH 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.